Ani pharmaceuticals to further expand rare disease business through acquisition of alimera sciences

Conference call scheduled for today at 8:30 a.m. et strengthens rare disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue adds two commercial assets iluvien ® and yutiq ® with significant growth potential, expanding ani's foothold in key strategic therapeutic area of ophthalmology anticipated to drive high single digit to low double digit accretion in adjusted non-gaap eps in 2025 and to be substantially accretive thereafter expected to generate additional $35 - $38 million in 2025 adjusted non-gaap ebitda inclusive of approximately $10 million in identified cost synergies; additional ebitda contribution expected from accelerated growth of purified cortrophin ® gel in ophthalmology increased geographic diversification with alimera's established ex-us footprint, including direct operations in europe princeton, n.j.
ANIP Ratings Summary
ANIP Quant Ranking